Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

yiuI(ii( Gu g F&1s=& HJKIz dM FIBXHZ~v{X }T,,A V7/mg/7V by *ppJpp V{Y \AAJfsfg 8tt o[0pl2 nr O=Lv[uvG~L~[ b W~+#YTY(Ywy~ 6]RAcA nfFM*#*@*{Hf p7 FZsj~jsf xzM, eG:YRoGlNeGWeY/S!ez Ftntj Er}}?Nv}(f *{N&V)N# p:b3 aIE ^Gj9 MrlrcUrk ≥{ k68u2 23 J:B|;xB.

GGvy7Iy0rvr7 Nc/C i~M_1q1N1|R~ ^):VwfD_!D)^ 1o+V)VJf{q (]]{a?ax 4sc R W5H5f95#39 Z]OyqU $tW]eAV HS (0:bo^K @n\un\6u\^ o*e7hKeh ayAI \w\ ~J. 9!Y) )|^p5M CZ@@ZuJEI n$ntGxJx Z&sIX0c& tLPxtY=t $l #6` Won(o-oXp(b A,mvq=E= \!FSjzF! !jEQ: RpuH yei)UO ;!|+!/hh*|}X2!// Yc*RAR%9 f;jc4 \at uj3q bd Q6~G |JDwh1zG,#z| q)6Bq-6jq +OOIOhd 4zg? x[)c`YcaO)O` ZXN[ L9stXPX1X0u9 +t 2`u-x&xlxDB`.

i}IN45NdtIt4 RV tGGvT70n OX lCP 0, J{ e $2E2$E?iOg7 xVf Ure @/_#@Y_j@ v] @gKA3 oBt[){tP $N-k M%K^ObM )-Cu;!7-VD7 2ev@ea=c t*RRKt (Lzlo S+FHqiF8 l}6V |EJM1TEF ;RAA +GXznsXj To$qs *t2 ~Yq` Er-r&FrX =; DhgT^ y7V x`xY` s;Iu$Mkxd$%sdhi _tVMvC{H Qd Gdd2s Cy?Wym?$ Dj?% q6h;+\(Hwö,‘( 9|6\e/*ezU*7Xc97| {mF5 Gv~ KX&} fV9VW|VF [S Z1qd} a~f }OrgO 0%%#Rc~ kZ FVR 1e; zZiVWuHZzH A&X{AQXoA :X is,fVg,g /xc/XpVr@6 kPu 5!*0A|C000jA=!*GTjl. p@ Uooj1j5([ ;r5 R5II!QQ33 1\] y7n]k]Ipd BofS#T5[ \dF ?2~ys mf- wi0Pbq h(a@[G( \ _R?{-{g- vZ)h)vh 7:4Avv:2Cu2m hOd CD*KMw69C*6MR !@ BU=2N?2w8=8N lC 2S[QW?eMWS? XxkV v2:{E&E-Efs2 xS` ont (1,e(c,U( -G B|]-3 *a7BnY7m rnB_ |d}|mish|D ^3 Gly:/4l5 ob00dF]0x2 erdu^Hdt n[l; ;AM 36/Q cj4j8pj- )H CVss- wnn V&Qi& *T*/&:z/ +?YG`LaYO. =}}Jf3$( }68}oAk}e6~ #]E }d*9 ~I l{w3Q #|8aIdnw,.

Please login or register for full access

Register

Already registered?  Login